From Lab To Launch: Navigating the Transition to Commercial Readiness
-
January 30, 2026
-
This article was originally published by Clinical Leader in January 2026. The publication is available at: https://www.clinicalleader.com/doc/from-lab-to-launch-navigating-the-transition-to-commercial-readiness-0001
The transition from late-stage clinical development into commercial readiness is a critical moment of transformation that many clinical-stage companies plan for too late. In this article, FTI Consulting’s Rick van der Vegte, Jim Polson, Michael Rachlin, Andrew Bonasera and Brendan Brbich explore why commercialization success is determined long before regulatory approval and why organizations that wait to prepare often struggle to translate scientific innovation into sustainable growth. Drawing on real-world experience across the biotech and life sciences industries, the authors examine how strategy, operations and capital must move in lockstep as companies approach pivotal trials, weigh go-it-alone versus partnership or transaction pathways and begin building scalable, compliant operating models. The piece offers leaders a practical framework for aligning commercialization decisions with investor expectations, operational readiness and long-term value creation.
Related Insights
Related Information
Published
January 30, 2026
Key Contacts
Senior Managing Director
Senior Managing Director
Senior Managing Director
Senior Managing Director
Managing Director